Adaptive changes results in activation of alternate signaling pathways and resistance to aromatase inhibitor resistance

Molecular and Cellular Endocrinology

Volumn 340, Issue 2, 2011, Pages 142-147

  Sabnis, Gauri ^a,b   Brodie, Angela ^a,b  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

Aromatase inhibitors; Breast cancer; Estrogen; Resistance

Indexed keywords

ANASTROZOLE; AROMATASE; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; GROWTH FACTOR RECEPTOR; LETROZOLE; MITOGEN ACTIVATED PROTEIN KINASE; SOMATOMEDIN RECEPTOR; TAMOXIFEN; TRASTUZUMAB;

ADAPTATION; BREAST CANCER; CANCER RESISTANCE; DRUG MECHANISM; DRUG RESPONSE; ENZYME ACTIVATION; ENZYME INHIBITION; HORMONE SENSITIVITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; AROMATASE INHIBITORS; DRUG RESISTANCE, NEOPLASM; HUMANS; MODELS, BIOLOGICAL; SIGNAL TRANSDUCTION; TRANSLATIONAL MEDICAL RESEARCH;

EID: 79960264282     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2010.09.005     Document Type: Review

References (22)

1. Chen S., Masri S., Wang X., Phung S., Yuan Y.C., Wu X. what do we know about the mechanisms of aromatase inhibitor resistanceŽ. J. Steroid Biochem. Mol. Biol. 2006, 102:232-240.
2. Howell A., Robertson J.F., Albano J., Quaresma A., Aschermannova L., Mauriac L., Kleeberg U.R., Vergote I., Erikstein B., Websterand A., Morris C. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J. Clin. Oncol. 2002, 20:3396-3403.
3. Hsu S.C., Hung M.C. Characterization of a novel tripartite nuclear localization sequence in the EGFR family. J. Biol. Chem. 2007, 282:10432-10440.
4. Jelovac D., Sabnis G., Long B.J., Macedo L., Goloubeva O.G., Brodie A.M. Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole. Cancer Res. 2005, 65:5380-5389.
5. Jelovac D., Macedo L., Goloubeva O.G., Handratta V., Brodie A.M.H. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model. Cancer Res. 2005, 65:5439-5444.
6. Leary A., Dowsett M. Combination therapy with aromatase inhibitors: the next era of breast cancer treatmentŽ. Br. J. Cancer 2006, 95:661-666.
7. Levin E.R., Pietras R.J. Estrogen receptors outside the nucleus in breast cancer. Breast Cancer Res. Treat. 2008, 108:351-361.
8. Lo H.W., Hung M.C. Nuclear EGFR signaling network in cancers: linking EGFR pathway to cell cycle progression, metric oxide pathway and patient survival. Br. J. Cancer 2007, 96(Suppl.):R16-20.
9. Lo H.W., Hsu S.C., Hung M.C. EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization. Breast Cancer Res. Treat. 2006, 95:211-218.
10. Long B.J., Jelovac D., Thiantanawat A., Brodie A.M. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model. Clin. Cancer Res. 2002, 8:2378-2388.
11. Long B.J., Jelovac D., Handratta V., Thiantanawat A., MacPherson N., Ragaz J., Goloubeva O.G., Brodie A.M. Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model. J. Natl. Cancer Inst. 2004, 96:456-465.
12. Macedo L., Sabnis G., Goloubeva O., Brodie A. Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model. Cancer Res. 2008, 68:3516-3522.
13. Nicholson R.I., Gee J.M. Estrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer. Br. J. Cancer 2000, 82:501-513.
14. Osborne C.K., Pippen J., Jones S.E., Parker L.M., Ellis M., Come S., Gertler S.Z., May J.T., Burton G., Dimery I., Webster A., Morris C., Elledge R., Buzdar A. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J. Clin. Oncol. 2002, 20:3386-3395.
15. Perey L., Paridaens R., Hawle H., Zaman K., Nolé F., Wildiers H., Fiche M., Dietrich D., Clément P., Köberle D., Goldhirsch A., Thürlimann B. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Ann. Oncol. 2007, 18:64-69.
16. Robertson J.F., Osborne C.K., Howell A., Jones S.E., Mauriac L., Ellis M., Kleeberg U.R., Come S.E., Vergote L., Gertler S., Buzdar A., Webster A., Morris C. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003, 98:229-238.
17. Sabnis G., Schayowitz A., Goloubeva O., Macedo L., Brodie A. Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen. Cancer Res. 2009, 69:1416-1428.
18. Santen R.J., Song R.X., McPherson R., Kumar R., Adam L., Jeng M.H., Yue W. The role of mitogen-activated protein (MAP) kinase in breast cancer. J. Steroid Biochem. Mol. Biol. 2002, 80:39-56.
19. Santen R.J., Song R.X., Zhang Z., Kumar R., Jeng M.H., Masamura A., Lawrence J., Berstein L., Yue W. Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity. Endocr. Relat. Cancer 2005, 12:S61-73.
20. Song R.X., Fan P., Yue W., Chen Y., Santen R.J. Role of receptor complexes in the extranuclear actions of estrogen receptor α in breast cancer. Endocr. Relat. Cancer 2006, 13(Suppl. 1):S3-S13.
21. Wang J.P., Conaway M., Masanura S., Li S., Santen R.J. Activation of the MAPK pathway enhances sensitivity of MCF-7 breast cancer cells to the mitogenic effect of estradiol. Endocrinology 2002, 143:3221-3229.
22. Xie Y., Hung M.C. Nuclear localization of p185neu tyrosine kinase and its association with transcriptional transactivation. Biochem. Biophys. Res. Commun. 1994, 203:1589-1598.